Prothena Corp Public Ltd Co (PRTA) SEC filings

PRTANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3017% below fair value

$8.16−0.07 (-0.85%)

Close on Nov 13, 2026Market cap $418.91MP/E –Yield –

SEC filings

40 of Prothena Corp Public's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Current report	8-K	Oct 28, 2026	Oct 29, 2026	SEC EDGAR
Current report	8-K	Oct 2, 2026	Oct 2, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	May 14, 2026	May 15, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 7, 2026	SEC EDGAR
Current report	8-K	May 7, 2026	May 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	May 14, 2026	Mar 27, 2026	SEC EDGAR
Current report	8-K	Feb 27, 2026	Feb 27, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Feb 27, 2026	SEC EDGAR
Current report	8-K	Feb 19, 2026	Feb 19, 2026	SEC EDGAR
Current report	8-K	Dec 10, 2025	Dec 12, 2025	SEC EDGAR
Current report	8-K	Nov 19, 2025	Nov 19, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Proxy statement	DEF 14A	Nov 19, 2025	Oct 7, 2025	SEC EDGAR
Current report	8-K	Aug 27, 2025	Aug 27, 2025	SEC EDGAR
Current report	8-K	Aug 6, 2025	Aug 6, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 4, 2025	SEC EDGAR
Current report	8-K	Aug 4, 2025	Aug 4, 2025	SEC EDGAR
Current report	8-K	Jul 30, 2025	Jul 30, 2025	SEC EDGAR
Current report	8-K	Jun 13, 2025	Jun 18, 2025	SEC EDGAR
Current report	8-K	Jun 15, 2025	Jun 16, 2025	SEC EDGAR
Current report	8-K	May 23, 2025	May 23, 2025	SEC EDGAR
Current report	8-K	May 13, 2025	May 16, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 8, 2025	SEC EDGAR
Current report	8-K	May 8, 2025	May 8, 2025	SEC EDGAR
Proxy statement	DEF 14A	May 13, 2025	Mar 28, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Feb 27, 2025	SEC EDGAR
Current report	8-K	Feb 20, 2025	Feb 20, 2025	SEC EDGAR
Current report	8-K	Dec 29, 2024	Dec 30, 2024	SEC EDGAR
Current report	8-K	Nov 12, 2024	Nov 12, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 12, 2024	SEC EDGAR
Current report	8-K	Sep 23, 2024	Sep 27, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	Aug 8, 2024	Aug 8, 2024	SEC EDGAR
Current report	8-K	May 24, 2024	May 28, 2024	SEC EDGAR
Current report	8-K	May 14, 2024	May 17, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Prothena Corp Public's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PRTA.

Compare: PRTA vs AMLX · PRTA vs BCYC · PRTA vs WVE · PRTA vs KROS · PRTA vs ENTA

Revenue growth347.4% · median 55.7%

Operating margin-64.6% · median -185.3%

Net margin-45.4% · median -161.2%

Company	Revenue	Growth
BCYC	$83.53M	+194.7%
WVE	$70.92M	–
ENTA	$65.26M	–
PRTA	$52.74M	+347.4%
KROS	$40.42M	-83.4%
AMLX	–	–

Company

Next earnings (est.): Feb 18, 2027, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 67
Held by institutions: 92.2%
Auditor: KPMG LLP
SEC CIK: 1559053

Advertisement
300 × 250

See a number that looks wrong?